Santarus Submits IND For Phase III Clinical Testing Of Rifamycin SV MMX In Travelers' Diarrhea
Links shared publicly online about this topic.
- 1,486total visits
Santarus Submits IND For Phase III Clinical Testing Of Rifamycin SV MMX In Travelers' Diarrhea
Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (F
View full resource at medicalnewstoday.com
Most Recently Shared on January 2, 2010 at 11:04 am By:
Santarus Submits IND For Phase III Clinical Testing Of Rifamycin SV MMX In Travelers' Diarrhea http://mnt.to/3vRd
Advertisement
